Astraveus is a two-year old start-up developing microfluidic automation for the production of cell and gene therapies (CGTs). These new kinds of therapies have tremendous potential, for example to cure cancers, but their accessibility is limited by industrial capacity and production cost. With several innovative and very high-performance technologies we aim at both bringing cost reduction and scale-up of CGT so that many more patients can be treated.

More information : RD-Engineer-Final-2018-1.pdf